All Supplementary Data from Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>In Vivo</i>
Hong Qin, Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Feng Wen(Shanghai Veterinary Research Institute), Wesley A. Cheng(City Of Hope National Medical Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), D. Lynne Smith, Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Han Sun(Soochow University), Zhenyuan Dong(Chinese Academy of Sciences), Soung-chul Cha(The University of Texas MD Anderson Cancer Center), Ippei Sakamaki(University of Toyama), Guo‐Wei Wei(Michigan State University), Laura Bover(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|236